Photo-Immunotherapy Boosts Nanoparticle Delivery to Tumors

Hisataka Kobayashi and his colleagues at NCI’s Center for Cancer Research employed a technique they call photo-immunotherapy, which uses an antibody linked to a light-sensitive compound or photosensitizer, to increase the leakiness of tumor-associated blood vessels. The resulting super-enhanced permeability…

Hisataka Kobayashi and his colleagues at NCI’s Center for Cancer Research employed a technique they call photo-immunotherapy, which uses an antibody linked to a light-sensitive compound or photosensitizer, to increase the leakiness of tumor-associated blood vessels. The resulting super-enhanced permeability and retention (SUPR) not only increased the amount of drug-loaded nanoparticles that accumulated in sensitized tumors, but more importantly, significantly reduced the size of treated tumors. The investigators report their work in the journal ACS Nano.

To create their photo-immunotherapy agent, the NCI team linked an FDA-approved monoclonal antibody, panitumumab, that targets the EGFR receptor variant, ErbB1, that is over-expressed on some solid tumors to a photosensitizing agent known as IR700. One day after injecting this agent into tumor-bearing mice, the investigators used a single dose of near-infrared light to activate the agent. They then injected panitumumab with a fluorescent label which could be imaged and found that the antibody rapidly accumulated only in the tumors that had been sensitized by irradiation and not in those that had not been sensitized.Subsequent experiments showed that the irradiated antibody-linked photosensitizer damages the first layer of tumor cells that sits next to the leaky blood vessels. When these cells are damaged, it changes the pressure around the blood vessels, causing them to expand, which increases their leakiness. The investigators demonstrated that the SUPR effect increases the permeability of these blood vessels to particles as large as 200 nanometers.In a final set of experiments, the researchers then administered commercially available liposome-encapsulated daunorubicin one hour after irradiation. Thirty days after 10 animals were treated, seven of the mice were still alive, compared to only one animal that was treated with liposomal daunorubicin alone.####About The National Cancer Institute (NCI)To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click
Contacts:National Cancer InstituteOffice of Technology & Industrial RelationsATTN: NCI Alliance for Nanotechnology in CancerBuilding 31, Room 10A4931 Center Drive , MSC 2580Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)
If you have a comment, please us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:

Related Links

Related News PressNews and information
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Govt.-Legislation/Regulation/Funding/Policy
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Nanomedicine
March 9th, 2013
March 9th, 2013
March 8th, 2013
March 7th, 2013
Discoveries
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013
Announcements
March 9th, 2013
March 9th, 2013
March 9th, 2013
March 9th, 2013